Melanoma Research Foundation Breakthrough Consortium Report issue

Foundation Phase 1 Phase 2

Organization Overview

First Clinical Trial
2013
NCT01841463
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Melanoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 6